Cellular immunotherapy using dendritic cells against multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2012-03-28 / Korean J Hematol 2012 Mar;47(1):17-27Cancer immunotherapy via dendritic cells
/in Dendritic Cells, International Publications /von 2012-03-22 / Nat. Rev. Cancer 2012 Mar;12(4):265-77Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2012-03-20 / Cancer Immunol. Immunother. 2012 Oct;61(10):1791-804Immunotherapy using dendritic cells against multiple myeloma: how to improve?
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2012-03-15 / Clin. Dev. Immunol. 2012;2012:397648Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination
/in Dendritic Cells, International Publications /von 2012-03-15 / J. Biomed. Biotechnol. 2012;2012:425476Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice
/in Breast Cancer, Dendritic Cells, International Publications /von 2012-03-07 / Breast Cancer Res. 2012 Mar;14(2):R39Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma
/in Dendritic Cells, Gallbladder Cancer, International Publications /von 2012-03-01 / J Hepatobiliary Pancreat Sci 2012 Mar;19(2):171-8Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provenge era
/in Dendritic Cells, International Publications, Prostate Cancer /von 2012-03-01 / Expert Rev Vaccines 2012 Mar;11(3):287-302Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2012-03-01 / Pancreas 2012 Mar;41(2):195-205IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de